Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Crescent Biopharma ( (CBIO) ).
On December 2, 2025, Crescent Biopharma entered into a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., involving two license agreements. Crescent granted Kelun-Biotech exclusive rights to develop and commercialize CR-001, a bispecific antibody, in Greater China, while Crescent received rights to develop SKB105, an integrin beta-6-directed ADC, outside Greater China. This collaboration is expected to enhance Crescent’s oncology pipeline and accelerate the development of combination therapies. Additionally, Crescent announced a private placement agreement on December 4, 2025, to raise approximately $185 million, which will fund its operations into 2028, supporting its strategic initiatives and clinical development programs.
The most recent analyst rating on (CBIO) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Crescent Biopharma stock, see the CBIO Stock Forecast page.
More about Crescent Biopharma
Crescent Biopharma is a biotechnology company focused on advancing therapies for cancer patients, with a pipeline that includes a PD-1 x VEGF bispecific antibody and novel antibody-drug conjugates (ADCs). The company aims to develop transformative therapies for solid tumors, leveraging multiple modalities and established targets.
Average Trading Volume: 100,859
Technical Sentiment Signal: Sell
Current Market Cap: $181.9M
For a thorough assessment of CBIO stock, go to TipRanks’ Stock Analysis page.